{"entity":{"id":"bespoke-crc","kind":"trial","name":"BESPOKE CRC","aka":["BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer"],"tldr":"Natera's US study in which 1,788 people with bowel cancer had Signatera blood tests after surgery and their doctors could act on the result; it records what changed and what happened, but does not randomise anyone.","summary":"BESPOKE CRC is Natera's prospective observational study of Signatera in resected colorectal cancer. The registry lists 1,788 participants, a start date of 24 April 2020 and a completion date of September 2025, with the overall status not updated. Because doctors chose treatment knowing the result, it can show how often a ctDNA result changes management and how ctDNA-positive and ctDNA-negative patients fare, but not whether acting on the test improves survival; that question belongs to DYNAMIC, CIRCULATE-US and VEGA.","status":"active","asOf":"2026-09-21","links":[{"label":"ClinicalTrials.gov NCT04264702","url":"https://clinicaltrials.gov/study/NCT04264702"}],"tags":["ctdna-roadmap"],"related":["circulate-us","ctdna-tests"],"cancers":["colorectal"],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":["signatera"],"companies":["natera"],"institutions":[],"pathways":[],"terms":["mrd","ctdna","tumour-informed-assay"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04264702","phase":"observational","setting":"Stage II to IV colorectal cancer after surgery in the United States: Signatera results returned to treating doctors, with treatment decisions and outcomes recorded","sponsor":"Natera, Inc.","enrolled":1788,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/bespoke-crc/","neighbours":{"trial":[{"id":"circulate-us","kind":"trial","name":"CIRCULATE-US","route":"/trials/circulate-us/"}],"roadmap":[{"id":"ctdna-tests","kind":"roadmap","name":"ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment","route":"/roadmaps/ctdna-tests/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/"}],"company":[{"id":"natera","kind":"company","name":"Natera","route":"/companies/natera/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"tumour-informed-assay","kind":"term","name":"Tumour-informed versus tumour-naive ctDNA assays","route":"/terms/tumour-informed-assay/"}]}}